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Objectives. To examine the predictive value of early improvement for short- and long-term outcome in the treatment of depressive
female inpatients and to explore the influence of comorbid disorders (CD). Methods. Archival data of a naturalistic sample of
277 female inpatients diagnosed with a depressive disorder was analyzed assessing the BDI at baseline, after 20 days and 30 days,
posttreatment, and after 3 to 6 months at follow-up. Early improvement, defined as a decrease in the BDI score of at least 30%
after 20 and after 30 days, and CD were analyzed using binary logistic regression. Results. Both early improvement definitions were
predictive of remission at posttreatment. Early improvement after 30 days showed a sustained treatment effect in the follow-up
phase, whereas early improvement after 20 days failed to show a persistent effect regarding remission at follow-up. CD were not
significantly related neither at posttreatment nor at follow-up. At no time point CDmoderated the prediction by early improvement.
Conclusions.We show that early improvement is a valid predictor for short-term remission and at follow-up in an inpatient setting.
CD did not predict outcome. Further studies are needed to identify patient subgroups amenable to more tailored treatments.
1. Introduction
Despite ongoing developments in the pharmacological and
psychotherapeutic treatment of depressive disorders, recur-
rent depressive illness remains one of the predominant
causes of disability worldwide [1, 2]. Therefore, it is nec-
essary to identify predictors of therapeutic outcomes to
further improve the development of effective treatments.
In treatment research, there is a wide agreement that the
combination of pharmacotherapy and psychotherapy is more
promising with respect to achieving remission and prevent-
ing relapse than either used alone [3–5]. Similarly, recent
meta-analyses have focused on the benefits of psychotherapy
in addition to pharmacotherapy alone and associate them
with a higher probability of remission and a lower risk of
relapse [4, 6].
Concerning the role of pharmacotherapy, findings
regarding the onset of the therapeutic effects of anti-
depressants have been heterogeneous. Several meta-analyses
showed that drug responses may occur within the first two
weeks [7–9]. However, a current meta-analysis by Iovieno
and Papakostas [10] shows a high heterogeneity in the relative
efficacy of pharmacotherapy in comparison to placebo in
several studies, and findings by Tedeschini et al. [11]
suggest that a minimum of four weeks is needed to reliably
detect drug versus placebo effects. Concerning the role of
psychotherapy, early gains have been identified as important
predictors of response and positive outcomes [12–14], as
well as of stable response and remission in the combined
depression treatment of outpatients in RCT designs [15–17].
Inpatients represent a substantial portion of the popu-
lation of depressed patients and act as the biggest driver of
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Figure 1: Flow chart: recruitment of patients.
costs in the treatment of depression [18]. The question arises
as to whether these previous findings can be generalized to
inpatient settings. It is reasonable to assume that patients
requiring inpatient care most likely suffer from more severe
depressive episodes [19]. Furthermore, the occurrence of
comorbid mental disorders has been found to be more
prevalent among more severely depressed patients [2]. As
a consequence, a higher number of confounding variables
including comorbid mental disorders should be considered
when investigating depressed inpatients.
Considering the high relapse rates for formerly depressed
patients [2], it is of particular importance to further examine
the sustainability of treatment effects after discharge. The
predictive value of early improvement has been studied in a
large naturalistic study of inpatients with major depression
fairly recently [20]. Yet, little is known about the sustainability
of treatment effects and the predictive value of early improve-
ment over an extended period of time. To our knowledge,
similar analyses of the influence of comorbid disorders do
not yet exist. Hence, the aim of this study was to analyze the
predictive value of early improvements on long-term effects
in a combined therapy for depressed female patients in a
naturalistic inpatient setting, taking comorbid disorders into
account. Compared to men, women have a twofold higher
risk for the development of a depressive disorder [21]; their
risk for disease recurrence is higher, and the duration of their
disease episodes is longer [2]. For all of these reasons, women
in particular represent a subpopulation worth researching for
specific outcome predictors.
2. Methods
2.1. Sample and Treatment. The current data were collected
in a private psychiatric hospital for women in Switzerland.
Whereas the clinic is privately run, it serves the community,
regardless of the patients’ type of insurance. All patients
meeting the diagnostic criteria for either a depressive episode
(F32) or a recurrent depressive disorder (F33) as first or
second diagnosis according to the ICD-10 [22] who were
being treated during the years 2005–2011 were eligible for
inclusion into the current analysis. Excluded were all patients
with other affective disorders, such as manic episodes (F30);
bipolar disorders (F31); and persistent (F34), other (F38), or
unspecified mood disorders (F39), and patients with insuffi-
cient German language skills (see Figure 1). For description
of comorbid disorders, persistent mood disorders (F34) were
included (see Table 2). Sociodemographic variables (age,
family status, education, and working status) were collected
through routine intake documentation. During the course
of treatment, this documentation was supplemented with
diagnostic and clinical data, such as disease specifiers (single
versus recurrent), comorbid disorders, and the number of
previous treatments.
Individual psychotherapies consisted of 3 to 4 sessions
of 50 minutes per week using cognitive-behavioral treatment
(CBT) interventions for depression [23] throughout the
whole stay. When indicated, significant others and relevant
persons from the professional environment were involved.
Finally, strategies for the maintenance of therapeutic gains
and relapse prevention were developed. In addition to CBT,
all patients participated in a standard group therapy pro-
gram consisting of assertiveness training, progressive muscle
relaxation, walking and movement therapy, and art and
occupational therapy. Almost all patients were also treated
with psychoactive medication (antidepressants, neuroleptics,
tranquilizer, or mood stabilizers) and if indicated, they
also received medication treatment for somatic disorders.
Table 1 gives an overview of the type of medication taken
at baseline and posttreatment. A clear majority was treated
with antidepressants, and this proportion increased at the
posttreatment stage. Additionally, the use of neuroleptics
and mood stabilizers increased. However, the prescription
of tranquilizers decreased considerably during treatment.
The same changes were found regarding combinations of an
antidepressant with any other medication category. In total,
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Table 1: Frequencies and changes in medications used over the course of treatment.
Medication type Baseline Posttreatment Change
Antidepressants 73.6% (𝑛 = 204) 82.3% (𝑛 = 228) 8.7% (𝑛 = 24)
Neuroleptics 22.4% (𝑛 = 62) 35.7% (𝑛 = 99) 13.3% (𝑛 = 37)
Tranquilizer 26.4% (𝑛 = 73) 7.9% (𝑛 = 22) −18.5% (𝑛 = 51)
Mood stabilizer 8.7% (𝑛 = 24) 14.8% (𝑛 = 41) 6.11% (𝑛 = 17)
Antidepressants + neuroleptics 25.5% (𝑛 = 52) 39.0% (𝑛 = 89) 13.5% (𝑛 = 37)
Antidepressants + tranquilizer 27.0% (𝑛 = 55) 9.6% (𝑛 = 22) −17.4% (𝑛 = 33)
Antidepressants + mood stabilizer 10.3% (𝑛 = 21) 14.5% (𝑛 = 33) 4.2% (𝑛 = 12)
Table 2: Types and frequencies of comorbid disorders (ICD-10).
Type of comorbid disorder 1st CD 2nd CD 3 and more CDs
(𝑛 = 182) (𝑛 = 87) (𝑛 = 41)
F0 organic, including symptomatic, mental disorders 2 0 0
F1 mental and behavioural disorders due to psychoactive substance use 18 12 15
F2 schizophrenia, schizotypal and delusional disorders 5 1 0
F34.1 dysthymic disorder 11 1 1
F4 neurotic, stress-related, and somatoform disorders 66 37 7
F5 behavioural syndromes associated with physiological disturbances and physical factors 16 10 2
F6 disorders of adult personality and behaviour 50 12 6
F7 mental retardation 1 1 1
F8 disorders of psychological development 0 0 0
F9 behavioural and emotional disorders with onset usually occurring in childhood and adolescence 5 6 6
Z factors influencing health status and contact with health services 8 7 3
eight of the 277 patients did not receive any medication,
neither at baseline nor at posttreatment. Due to the vast
number of possible combinations, we did not include this
information in the analyses.
2.2. Data Collection and Definitions. The archival data used
were collected using a naturalistic design. The data were
archived anonymously and did not allow for any personal
identification. Feedback on the progress of symptoms was
supplied for the treated patients. As data collection was
conducted before and independent of this analysis, there
was no interference with the aim of the present investiga-
tion of outcome predictors. The research was conducted in
accordance with the American Psychological Association’s
ethical principles [24] and in compliance with precepts of the
Declaration of Helsinki [25].
Subjects rated the severity of their depressive symptoms
using the Beck Depression Inventory (BDI) [26] at the begin-
ning and at the end of the treatment, as well as every ten days
during treatment. Remission at the time points posttreatment
and at follow-upwas defined asmeasuring a BDI score of 11 or
less [26]. This study focuses on assessments at baseline, after
20 days, after 30 days after treatment, and throughout follow-
up (three to six months after hospitalization; 𝑀 = 133.68,
SD = 25.76 days). Patients with missing values for any of the
five assessments were excluded (see Figure 1). Owing to the
investigation of treatment sustainability at follow-up, the loss
of a considerable number of patients to attrition (𝑁 = 813)
was accepted.
Early improvement was defined as a decrease in the
BDI score of at least 30%, compared to the baseline value,
according to a naturalistic study by Henkel et al. [20].
According to the literature, there are different time points
from 2 up to 8 weeks after baseline when early improvement
is measured [15–17, 20]. We have decided to conduct our
analyses for two different time points: after 20 days and after
30 days after baseline assessment. The latter considers the
required minimum of four weeks of medication use, which is
intended to minimize the contribution of placebo effects [11].
The early improvement variable was coded dichotomously,
dividing the sample into two subgroups: nonearly improvers
and early improvers, reported in the following as EI20/NEI20
(𝑛 = 160; 𝑛 = 117) and EI30/NEI30 (𝑛 = 176; 𝑛 = 101) for
measurements after 20 and 30 days of treatment, respectively.
To investigate the influence of comorbid disorders, the
variable comorbid disorders with two dichotomous values
(CD/NCD) was defined: no comorbid disorder (NCD) (𝑛 =
95), and any comorbid disorder(s) (CD) (𝑛 = 182). The
types and combinations of one or more present comorbid
disorder in our sample cover an extensive range of ICD-10
diagnosis formental and behavioral disorders. Because of this
heterogeneity a further categorization of the type or number
of comorbid disorders was not conceivable in this study. The
descriptive data of all comorbid disorders can be found in
Table 2.
2.3. Statistical Analyses. All statistical calculations were per-
formed using the PASWVersion 18 forWindows. To describe
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Table 3: Demographic and clinical characteristics of subjects by study groups.
Characteristics
Group with early
improvement
(EI30)
Group without
early improvement
(NEI30) 𝜒
2/𝑡 df P value
𝑁 = 176 𝑁 = 101
Average age (years) 45.50 (SD = 16.72) 39.93 (SD = 14.16) −2.817 275 .005
Family status
Single 25.6% (𝑛 = 45) 26.7% (𝑛 = 27)
.979 2 .614Married/with partner 59.7% (𝑛 = 105) 54.5% (𝑛 = 55)
Divorced/widowed 14.8% (𝑛 = 26) 18.8% (𝑛 = 19)
Education
Primary and secondary school 75.6% (𝑛 = 133) 83.2% (𝑛 = 84)
2.433 2 .295Upper secondary school (matura) 14.8% (𝑛 = 26) 8.9% (𝑛 = 9)
University or other tertiary education 9.7% (𝑛 = 17) 7.9% (𝑛 = 8)
Working status
Full-time/part-time 36.4% (𝑛 = 64) 41.6% (𝑛 = 42)
1.787 3 .650Unemployed 60.2% (𝑛 = 106) 56.4% (𝑛 = 57)
Student 2.8% (𝑛 = 5) 1.0% (𝑛 = 1)
Retired 0.6% (𝑛 = 1) 1.0% (𝑛 = 1)
Depressive disorder
First episode 25.6% (𝑛 = 45) 23.8% (𝑛 = 24) .112 1 .775
Recurrent episode 74.4% (𝑛 = 131) 76.2% (𝑛 = 77)
Comorbid disorder
No 43.2% (𝑛 = 76) 18.8% (𝑛 = 19) 16.913 1 .000
Yes 56.8% (𝑛 = 100) 81.2% (𝑛 = 82)
Number of inpatient treatments 1.17 (SD = 1.72) 1.37 (SD = 1.74) .910 275 .364
Number of outpatient treatments 1.09 (SD = .987) 1.29 (SD = 1.08) 1.538 275 .125
Treatment duration 85.88 (SD = 36.41) 114.50 (SD = 39.49) 6.106 275 .000
the two study groups with and without early improvement
and to investigate differences in demographic and clinical
characteristics, two-tailed unpaired 𝑡-tests and 𝜒2-tests were
computed. Binary logistic regression analyses were computed
to examine the association of the variables early improvement
and comorbid disorders with remission or nonremission at
posttreatment and at follow-up, controlling for the variables
baseline BDI, age, and treatment duration.
3. Results
3.1. Description of the Sample. The sample consisted of 𝑁 =
277 patients, whose demographics and clinical characteristics
are described in Table 3 for the subgroups EI30 and NEI30.
Because results did not differ for the subgroups EI20 and
NEI20we did not report this data separately. For lack of space,
we also chose to focus in the text on the early improvement
definitionmade 30 days after baseline (EI30/NEI30), whereas
results for EI30/NEI30 are given in the tables.
Table 3 reports the sample demographics. Of demo-
graphic variables, only average age differed significantly
between EI30 und NEI30. Whereas the occurrence of a
single or recurrent depressive episode showed no significant
differences in the subgroups, comorbid disorders were diag-
nosed for about two-thirds of the patients, and differed in
distribution betweenEI30 andNEI30. Regarding previous in-
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Figure 2: BDI scores overtime by study groups EI30 and NEI30.
or outpatient treatments, no significant differences between
the subgroups were found. However, treatment duration was
significantly longer for patients in the NEI30 subgroup.
Table 4 reports BDI scores at baseline, 30 days, posttreat-
ment, and follow-up. These BDI scores were used as the
base of further analyses using binary logistic regression. As
can be seen in Figure 2 displaying the change of the BDI
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Table 4: Descriptives by study group and time of measurement.
Descriptives by study groups Baseline BDI
mean (SD)
30 days BDI
mean (SD)
Posttreatment BDI
mean (SD)
Follow-up BDI
mean (SD)Early improvement Comorbid disorders
NEI30
NCD (𝑛 = 19) 25.63 (13.24) 23.47 (12.41) 9.42 (5.95) 9.89 (8.56)
CD (𝑛 = 82) 28.04 (11.71) 26.44 (12.09) 17.04 (12.22) 19.13 (14.59)
Total (𝑛 = 101) 27.59 (11.98) 25.88 (12.15) 15.60 (11.67) 17.40 (14.10)
EI30
NCD (𝑛 = 76) 23.82 (9.83) 9.04 (6.69) 6.12 (5.71) 7.84 (8.11)
CD (𝑛 = 100) 24.93 (9.22) 10.51 (6.62) 7.12 (6.26) 10.23 (9.58)
Total (𝑛 = 176) 24.45 (9.48) 9.87 (6.67) 6.69 (6.03) 9.20 (9.03)
Total
NCD (𝑛 = 95) 24.18 (10.55) 11.93 (9.95) 6.78 (5.88) 8.25 (8.20)
CD (𝑛 = 182) 26.34 (10.50) 17.69 (12.35) 11.59 (10.62) 14.24 (12.85)
Total (𝑛 = 277) 25.60 (10.55) 15.71 (11.89) 9.94 (9.53) 12.19 (11.80)
scores for the subgroups EI30 and NEI30 over time, the BDI
scores of the EI30 group reached the level of remission status
after 30 days (≤11 points) and remained below the threshold
throughout the observation time.
3.2. PosttreatmentOutcomes. Thevariables baseline BDI, age,
and treatment duration differed significantly between the
subgroups EI20 and NEI20, as well as between EI30 and
NEI30 (Table 3), so that we included these variables in the
binary logistic regression as covariates. Whereas for early
improvement at 30 days, baseline BDI and treatment duration
showed a significant effect, age did not. After controlling for
these covariates, the factor EI30/NEI30 showed a significant
effect on remission at posttreatment (Table 6) showing that
patients with early improvement had a higher probability
to remit. However, neither comorbid disorders (CD/NCD)
nor their interaction with early improvement (EI30/NEI30)
predicted remission at posttreatment.The regression analysis
with EI20/NEI20 displays similar results as the EI30/NEI30
calculations (Table 5).
3.3. Follow-Up Outcomes. Analysis of EI30/NEI30 showed
a significant effect of baseline BDI on remission, whereas
treatment duration and age did not. After controlling for
these covariates, the factor EI30/NEI30 showed a significant
effect on remission at follow-up. Patients with early improve-
ment had a higher probability of remission. The factor
comorbid disorders (CD/NCD) and its interaction with early
improvement (EI30/NEI30) did not have any significant
effect regarding remission at follow-up (Table 6). For early
improvement after 20 days, binary logistic regression yielded
little differences in results compared to the improvement
after 30 days. However, the early improvement (EI20/NEI20)
is not predicting remission beyond posttreatment (Table 5).
In addition, treatment duration had a significant effect on
remission.
4. Discussion
Recently, several studies and meta-analyses have addressed
the predictive value of an early improvement pattern in
combination with treatment of CBT and antidepressant
medication. However, most of these analyses were conducted
in an outpatient setting and did not extend to a time horizon
beyond 10 weeks. This study investigates whether early
improvement is also a valid predictor for treatment response
and long-term sustainability of combined psychotherapy and
pharmacotherapy in depressed female subjects in an inpatient
clinic. Commonly, an inpatient population presents a range
from mild to severe symptoms of depression.
After controlling for baseline severity of depressive
symptoms, age, and treatment duration, patients with early
improvement had a higher probability to show remission at
posttreatment. Early improvement was predictive for remis-
sion independent of any comorbid disorders. Patients with or
without comorbid disorders (CD/NCD) did not differ in their
treatment outcomes regarding remission, nor did CD/NCD
interact with early improvement in the prediction of out-
comes. These findings occurred in both early improvement
after 20 days and after 30 days of treatment. At posttreatment
both early improvement definitions had the same explanatory
power concerning the prediction of remission.
The overall depressionmean showed amanifest improve-
ment as compared to baseline three to six months after
termination of inpatient treatment (see Figure 2 and Table 4).
However, mean BDI scores increased from posttreatment to
follow-up by 2.25 BDI points so that the average BDI score
over all patients cannot be considered as remission of the
total group anymore (Table 4). Nevertheless, the distinction
between early improvers and nonearly improvers provides
interesting information. Patients who show early improve-
ment after 30 days of treatment have a significantly higher
probability to still be a “remitter” at follow-up.This prediction
can only bemade based on the early improvement assessment
after 30 days, whereas the early improvement after 20 days
does not offer this predictive information. Comorbidity
during follow-up neither has a significant predictive value
nor is it indicative of a detectable interaction with early
improvement.
Our findings on significant outcome predictors are in
accordance with comparable findings in RCTs with out-
patient samples [15–17] and in a naturalistic study with
inpatients [20]. The definition of early improvement as a
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Table 5: Binary logistic regression analyses of the covariates/factors associated with treatment outcome at posttreatment and follow-up for
the early improvement definition after 20 days (EI20/NEI20).
𝐵 (SE) OR 95% CI 𝑃 value
Posttreatment
Baseline BDI −.11 (.02) .89 .86–.93 .000
Treatment duration −.01 (.01) .99 .98–1.00 .016
Age .00 (.01) 1.00 .98–1.02 .997
EI20/NEI20 −1.15 (.39) .315 .15–.67 .003
CD/NCD .18 (.46) 1.19 .48–2.95 .705
Interaction EI20/NEI20 × CD/NCD .71 (.74) 2.04 .48–8.78 .337
Follow-up
Baseline BDI −.06 (.02) .94 .92–.97 .000
Treatment duration −.01 (.01) 1.00 .96–1.00 .048
Age .01 (.01) 1.01 1.00–1.03 .142
EI20/NEI20 −.53 (.33) .59 .31–1.13 .114
CD/NCD .26 (.38) 1.30 .62–2.71 .493
Interaction EI20/NEI20 × CD/NCD .46 (.63) 1.58 .46–5.40 .468
Table 6: Binary logistic regression analyses of the covariates/factors associated with treatment outcome at posttreatment and follow-up for
the early improvement definition after 30 days (EI30/NEI30).
𝐵 (SE) OR 95% CI 𝑃 value
Posttreatment
Baseline BDI −.12 (.02) .89 .86–.92 .000
Treatment duration −.01 (.01) .99 .98–1.00 .023
Age −.00 (.01) .99 .98–1.02 .913
EI30/NEI30 −1.29 (.39) .28 .13–.59 .001
CD/NCD .15 (.44) 1.16 .49–2.72 .739
Interaction EI30/NEI30 days × CD/NCD .90 (.82) 2.45 .50–12.13 .272
Follow-up
Baseline BDI −.06 (.01) .94 .92–.97 .000
Treatment duration −.01 (.00) .99 .99–1.00 .076
Age .01 (.01) 1.01 1.00–1.03 .148
EI30/NEI30 −.92 (.34) .40 .21–.78 .007
CD/NCD .04 (.36) 1.04 .51–2.11 .909
Interaction EI30/NEI30 × CD/NCD 1.18 (.69) 3.25 8.34–12.67 .089
decrease of 30% in BDI score compared to baseline for the
two measurement times after 20 days and after 30 days of
treatment does not provide any differential prediction for
remission at posttreatment. But for remission at follow-up
the assessment after 30 days offers predictive information,
whereas the measurement after 20 does not. Furthermore,
placebo effects of pharmacotherapy as a potential explanation
for early symptom reduction are minimized [11]. In a long-
term perspective, measuring early improvement after 30
days provides the advantage of a more reliable prediction.
However, future research will need to define a consensual
maximum time limit for labeling improvements as “early.”
In general, attention should be paid to the aggravation
of the self-reported depressive symptoms from posttreatment
to follow-up, represented in a reincrease of the BDI scores
after termination of inpatient treatment (Table 4). Obviously,
not all patients achieve a satisfying transfer of in-therapy
gains into their customary environments. This observation
might be explained by the relative stability of the social
network in comparison to the patient’s psychological func-
tioning, whichmost likely has undergone substantial changes
during treatment, as long as it was not integrated into the
inpatient treatment. In the inpatient setting, moreover, the
relational environment is considered a particularly important
factor with high therapeutic potential; the ward has its own
social environment, including other inpatients and health-
care professionals, in addition to specific group therapies
and activities [27]. As a consequence, it seems reasonable
to expect a destabilization of the patient’s well-being, once
having to do without this support and being back in their
largely unchanged social network [28]. Consequently, when
investigating the symptom trajectories of former inpatients
over longer periods, these are factors to be incorporated into
the investigation.
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Neither the existence of comorbid disorders at baseline
nor related interaction with early improvement significantly
predicted remission. These findings were in contrast to
our expectations, given the fact that comorbid disorders
had previously been found to be associated with a greater
severity of symptoms and lower treatment response rates [2].
However, the descriptives in Table 4 show that patients with
CD and without early improvement evidently display higher
BDI scores than the other patients. Consequently, it may be
assumed that the patients with CD present with themost het-
erogeneous and complex problem pattern. As a consequence
further research may better capture the complexity of these
patients’ problems at intake.
Our study has several limitations. It is based on nat-
uralistic inpatient data, and thus several factors could not
be controlled for, such as a further distinction of comorbid
disorders, their treatment during the stay, or any treatments
thereafter. Additionally, due to the power restrictions, the
differential effects of various antidepressant medications and
combinations with other psychotropic drugs could not be
analyzed in detail. Nevertheless, it seems worth mentioning
that the prescription of antidepressants, neuroleptics, and
mood stabilizers increased from baseline to posttreatment,
whereas the use of tranquilizers decreased. This scheme
represents common clinical practice in the time course of
a state-of-the-art treatment of depressive patients. Whereas
our findings for female inpatients are not generalizable to
males, they do have a significant clinical relevance, given that
females account for two-thirds of all depressed patients [21].
5. Conclusion
In summary, we replicated the previous findings on the pre-
dictive value of early improvement for outcomes at treatment
termination in a naturalistic inpatient setting. In addition, we
can confirm the predictive value of early improvement also in
a long-term perspective. We showed that early improvement
is associated with remission at the end of the hospitalization
and at follow-up three to six months thereafter.The diagnosis
of comorbid disorders did not allow for better outcome
predictions, which is probably due to the heterogeneity of
this group. Future research may assess the treatment of
comorbid mental disorders, as well as the recovery process in
greater detail, accounting for other factors, such as treatment
methods, the therapeutic relationship, patient expectations,
and therapist influences [29]. Furthermore, a closer investi-
gation of gender-specific factors in inpatient treatment and
the transfer of the treatment benefits into daily life in the
customary environment may also promise further advances
in the care of depressed inpatients.
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